Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?

Introduction. Anticoagulants such as argatroban and heparins (low-molecular-weight and unfractionated) play an immense role in preventing thromboembolic complications in clinical practice. Nevertheless, they can also have a negative effect on the immune system. This study is aimed at investigating t...

Full description

Saved in:
Bibliographic Details
Main Authors: Andre Bredthauer, Manuel Kopfmueller, Michael Gruber, Sophie-Marie Pfaehler, Karla Lehle, Walter Petermichl, Timo Seyfried, Diane Bitzinger, Andreas Redel
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2020/9783630
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568131004923904
author Andre Bredthauer
Manuel Kopfmueller
Michael Gruber
Sophie-Marie Pfaehler
Karla Lehle
Walter Petermichl
Timo Seyfried
Diane Bitzinger
Andreas Redel
author_facet Andre Bredthauer
Manuel Kopfmueller
Michael Gruber
Sophie-Marie Pfaehler
Karla Lehle
Walter Petermichl
Timo Seyfried
Diane Bitzinger
Andreas Redel
author_sort Andre Bredthauer
collection DOAJ
description Introduction. Anticoagulants such as argatroban and heparins (low-molecular-weight and unfractionated) play an immense role in preventing thromboembolic complications in clinical practice. Nevertheless, they can also have a negative effect on the immune system. This study is aimed at investigating the influence of these substances on polymorphonuclear neutrophils (PMNs), whose nonspecific defense mechanisms can promote thrombogenesis. Methods. Blood samples from 30 healthy volunteers were investigated, whereby PMNs were isolated by density gradient centrifugation and incubated with 0.8 μg/mL of argatroban, 1.0 U/mL of low-molecular-weight heparin (LMWH), 1.0 U/mL of unfractionated heparin (UFH), or without drug (control). A collagen-cell mixture was prepared and filled into 3D μ-slide chemotaxis chambers (IBIDI® GmbH, Germany). Stimulation was initiated by using a chemokine gradient of n-formyl-methionine-leucyl-phenylalanine (fMLP), and microscopic observation was conducted for 4.5 hours. The cells’ track length and track straightness, as well as the number of attracted granulocytes, level of ROS (reactive oxygen species) production, and NET (neutrophil extracellular traps) formation, were analyzed and categorized into migration distances and time periods. Results. All three anticoagulants led to significantly reduced PMN track lengths, with UFH having the biggest impact. The number of tracks observed in the UFH group were significantly reduced compared to the control group. Additionally, the UFH group demonstrated a significantly lower track straightness compared to the control. ROS production and NET formation were unaffected. Conclusion. Our data provide evidence that anticoagulants have an inhibitory effect on the extent of PMN migration and chemotactic migration efficiency, thus indicating their potential immune-modulatory and prothrombotic effects.
format Article
id doaj-art-22234ea6a8b54356810d95c976110253
institution Kabale University
issn 1755-5914
1755-5922
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj-art-22234ea6a8b54356810d95c9761102532025-02-03T00:59:41ZengWileyCardiovascular Therapeutics1755-59141755-59222020-01-01202010.1155/2020/97836309783630Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?Andre Bredthauer0Manuel Kopfmueller1Michael Gruber2Sophie-Marie Pfaehler3Karla Lehle4Walter Petermichl5Timo Seyfried6Diane Bitzinger7Andreas Redel8Department of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Cardiothoracic Surgery, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyDepartment of Anesthesiology, University Medical Center Regensburg, Regensburg, GermanyIntroduction. Anticoagulants such as argatroban and heparins (low-molecular-weight and unfractionated) play an immense role in preventing thromboembolic complications in clinical practice. Nevertheless, they can also have a negative effect on the immune system. This study is aimed at investigating the influence of these substances on polymorphonuclear neutrophils (PMNs), whose nonspecific defense mechanisms can promote thrombogenesis. Methods. Blood samples from 30 healthy volunteers were investigated, whereby PMNs were isolated by density gradient centrifugation and incubated with 0.8 μg/mL of argatroban, 1.0 U/mL of low-molecular-weight heparin (LMWH), 1.0 U/mL of unfractionated heparin (UFH), or without drug (control). A collagen-cell mixture was prepared and filled into 3D μ-slide chemotaxis chambers (IBIDI® GmbH, Germany). Stimulation was initiated by using a chemokine gradient of n-formyl-methionine-leucyl-phenylalanine (fMLP), and microscopic observation was conducted for 4.5 hours. The cells’ track length and track straightness, as well as the number of attracted granulocytes, level of ROS (reactive oxygen species) production, and NET (neutrophil extracellular traps) formation, were analyzed and categorized into migration distances and time periods. Results. All three anticoagulants led to significantly reduced PMN track lengths, with UFH having the biggest impact. The number of tracks observed in the UFH group were significantly reduced compared to the control group. Additionally, the UFH group demonstrated a significantly lower track straightness compared to the control. ROS production and NET formation were unaffected. Conclusion. Our data provide evidence that anticoagulants have an inhibitory effect on the extent of PMN migration and chemotactic migration efficiency, thus indicating their potential immune-modulatory and prothrombotic effects.http://dx.doi.org/10.1155/2020/9783630
spellingShingle Andre Bredthauer
Manuel Kopfmueller
Michael Gruber
Sophie-Marie Pfaehler
Karla Lehle
Walter Petermichl
Timo Seyfried
Diane Bitzinger
Andreas Redel
Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
Cardiovascular Therapeutics
title Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
title_full Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
title_fullStr Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
title_full_unstemmed Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
title_short Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
title_sort therapeutic anticoagulation with argatroban and heparins reduces granulocyte migration possible impact on ecls therapy
url http://dx.doi.org/10.1155/2020/9783630
work_keys_str_mv AT andrebredthauer therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT manuelkopfmueller therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT michaelgruber therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT sophiemariepfaehler therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT karlalehle therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT walterpetermichl therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT timoseyfried therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT dianebitzinger therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy
AT andreasredel therapeuticanticoagulationwithargatrobanandheparinsreducesgranulocytemigrationpossibleimpactoneclstherapy